If you or a loved one is on Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. For decades, pharmacovigilance research has established that certain factors—such as JC virus antibody status, duration of therapy, and prior immunosuppressant use—significantly influence PML risk. This page reviews the key risk factors clinicians evaluate to guide monitoring and early detection.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in immunocompromised patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive impairment, vision changes, and coordination difficulties. The FDA Adverse Event Reporting System (FAERS) data for Tysabri lists fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, balance disorder, cognitive disorder, and muscular weakness among the most frequently reported adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they reflect the types of neurological symptoms that may be associated with the condition.
The mechanistic link between Tysabri and PML involves the drug's mode of action. Tysabri is an alpha-4 integrin antagonist that prevents immune cells from crossing the blood-brain barrier. This immunosuppressive effect within the central nervous system can allow the JC virus, which is normally controlled by the immune system, to reactivate and cause PML. The risk is highest in patients who are anti-JCV antibody positive, have been on Tysabri for more than two years, or have previously used immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning on Tysabri clearly states the increased risk of PML and identifies the three known risk factors. However, questions may arise about whether the warnings were adequate for individual patients, particularly regarding the timing and clarity of risk communication. For example, patients may not have been fully informed about the significance of anti-JCV antibody testing or the cumulative risk over time. The prescribing information advises that physicians should consider whether the expected benefit of Tysabri is sufficient to offset the PML risk when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). If a patient was not adequately warned or monitored, this could be a factor in legal claims.
For patients in Michigan who have developed PML after Tysabri treatment, consulting with an attorney experienced in pharmaceutical litigation is important. The statute of limitations for product liability claims in Michigan is generally three years from the date of injury or from when the injury was discovered or should have been discovered. This timeline is critical because PML can have a delayed onset, and symptoms may initially be mistaken for multiple sclerosis relapse. The date of diagnosis or the date when a reasonable person would have connected the symptoms to Tysabri may start the clock. Given that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), prompt legal evaluation is essential. The timeline between Tysabri exposure and PML diagnosis can vary. The risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur earlier, particularly in patients with additional risk factors. The onset of symptoms may be gradual, and diagnosis often requires MRI imaging and cerebrospinal fluid analysis for JC virus DNA. This latency period can complicate the determination of when the statute of limitations begins. An attorney can help assess the specific facts of each case, including the date of Tysabri initiation, the date of PML diagnosis, and any prior immunosuppressant use.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Michigan, the statute of limitations for product liability claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For PML, this may be the date of diagnosis or when symptoms were reasonably connected to Tysabri. Prompt legal consultation is advised.
The three known risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These are identified in the Tysabri prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.